TSHA
Taysha Gene Therapies IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.96B
P/E Ratio
—
EPS
$-0.38
Beta
1.23
52W High
$7.30
52W Low
$2.21
50-Day MA
$5.20
200-Day MA
$4.46
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
Fundamentals
| Revenue (TTM) | $7.47M |
| Gross Profit (TTM) | $7.47M |
| EBITDA | $-131.41M |
| Operating Margin | -1774.00% |
| Return on Equity | -97.30% |
| Return on Assets | -37.80% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.87 |
| Price-to-Book | 9.25 |
| Price-to-Sales (TTM) | 261.94 |
| EV/Revenue | 234.67 |
| EV/EBITDA | -0.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 171.30% |
| Shares Outstanding | $287.36M |
| Float | $198.56M |
| % Insiders | 10.62% |
| % Institutions | 95.89% |
Historical Volatility
HV 10-Day
46.04%
HV 20-Day
101.75%
HV 30-Day
92.81%
HV 60-Day
77.14%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($11.86 target)
3
Strong Buy11
BuyMore HEALTHCARE Stocks
Data last updated: 5/11/2026